The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation

References

• Allebeck P. Schizophrenia: A life-shortening illness. Schizophr Bull 1989; 15: 81–89
   PubMed Web of Science ®Google Scholar
• Abrams CS, Brass LF. Platelet signal transduction. Hemostasis and thrombosis, basic principles and clinical practice. Chapter 31, RW Colman, et al. Lippincott Williams and Wilkins, Philadelphia, PA 2001; 541–559
   Google Scholar
• Bakken AM, Staeffler A, Jorgensen HA, Holmsen H. Glycerophospholipid molecular species in platelets and brain tissues – are platelets a good model for neurons?. Platelets 2006; 17: 484–492
   PubMed Web of Science ®Google Scholar
• Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927–929
   PubMed Web of Science ®Google Scholar
• Brown S. Excess mortality of schizophrenia: meta-analysis. Br J Psychiatry 1997; 171: 502–508
   PubMed Web of Science ®Google Scholar
• Brydon L, Magid K, Steptoe A. Platelets, coronary heart disease, and stress. Brain Behav Immun 2006; 20: 113–119
   PubMed Web of Science ®Google Scholar
• Cadet JL, Lohr J.B. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann NY Acad Sci 1989; 570: 176–185
   PubMed Web of Science ®Google Scholar
• De Clerk F. The role of serotonin in thrombogenesis. Clin Physiol Biochem 1990; 8(Suppl 3)40–49
   PubMedGoogle Scholar
• De Clerck F, Somers Y, Mannaert E, Greenspan A, Eerdekens M. In vitro effects of risperidone and 9-hydroxyrisperidone on human platelet function, plasma coagulation, and fibrynolysis. Clin Ther 2004; 26: 1261–1273
   PubMed Web of Science ®Google Scholar
• Dietrich-Muszalska A. Evaluation of the effects of different concentrations of risperidone, corresponding to the drug doses used in treatment of schizophrenic patients, on lipid peroxidation in plasma and blood platelets at in vitro studies. Psychiatr Psychol Klin 2004; 4: 215–223
   Google Scholar
• Dietrich-Muszalska A. The impact of different concentrations of clozapine on changes of lipid peroxidation in human plasma – in vitro studies. Psychiatr Psychol Klin 2005; 1: 18–25
   Google Scholar
• Dietrich-Muszalska A, Olas B. Isoprostanes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry 2007a; 11: 1–7
   Google Scholar
• Dietrich-Muszalska A, Olas B. The changes of aggregability of blood platelets in schizophrenia. World J Biol Psychiatry 2007b; 14: 1–6
   Google Scholar
• Dietrich-Muszalska A, Rabe-Jablonska J, Zgirski A. The effects of olanzapine (Zolafren) on lipid peroxidation in human blood platelets and plasma: in vitro studies. Psychiatr Psychol Klin 2004; 4: 13–19
   Google Scholar
• Dietrich-Muszalska A, Olas B, Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005; 16: 386–391
   PubMed Web of Science ®Google Scholar
• Dinan TG. Neuroleptic effects on platelet aggregation: a study in normal volunteers and schizophrenics. Psychol Med 1987; 17: 875–881
   PubMed Web of Science ®Google Scholar
• Doolittle RF, Watt KWK, Cottrell BA, Strong DD, Riley M. The amino acid sequence of the alpha-chain of human fibrinogen. Nature 1979; 280: 464–468
   PubMed Web of Science ®Google Scholar
• Eerdekens M, Hove IV, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004; 70: 91–100
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6: 132–191
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006; 7: 5–40
   PubMed Web of Science ®Google Scholar
• Farrel DH, Thiagarajan P, Chung DW, Davie EW. Role of fibrinogen and chain sites in platelet aggregation. Proc Natl Acad Sci USA 1992; 89: 10729–10732
   PubMedGoogle Scholar
• Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 2005; 25: 2043–2053
   PubMed Web of Science ®Google Scholar
• Frolich KW, Aarbakke GM, Holmsen H. Chlorpromazine increases the turnover of metabolically active phosphoinositides and elevates the steady state level of phosphatidylinositol-4-phosphate in human platelets. Biochem Pharmacol 1992; 44: 2013–2020
   PubMedGoogle Scholar
• Gachet C, Cazenave JP. Platelet receptors: ADP. Platelets in thrombotic and non-thrombotic disorders, P Gresele, CP Page, V Fuster, J Vermylen. Cambridge University Press, Cambridge 2002; 127–139
   Google Scholar
• Haslam RJ. Interaction of the pharmacological receptors of blood platelets with adenylate cyclase. Ser Haematol 1973; 6: 333–350
   PubMedGoogle Scholar
• Ishigooka J, Shizu Y, Wakatabe H, Tanaka K, Miura S. Different effects of centrally acting drugs on rabbit platelet aggregation; with special reference to selective inhibitory effects of antipsychotic and antidepressants. Biol Psychiatry 1985; 20: 866–873
   PubMedGoogle Scholar
• Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Arunoma OI, et al. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol 1995; 49: 359–365
   PubMed Web of Science ®Google Scholar
• Kamath S, Blann AD, Lip GYH. Platelet activation: assessment and quantification. Eur Heart J 2001; 22: 1561–1571
   PubMed Web of Science ®Google Scholar
• Laasvatn KO, Holmsen H. Chlorpromazine and human platelet glycerolipid metabolism: precursor specificity and significance of drug–platelet interaction time. Biochem Pharmacol 1999; 44: 1113–1123
   Google Scholar
• Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990; 15: 535–539
   Google Scholar
• McNicol A. Platelet preparation and estimation of functional responses. Platelets. A practical approach, SP Watson, KS Authi. Oxford University Press, Oxford, New YorkTokyo 1995; 1–6
   Google Scholar
• McNicol A, Israels SJ. Platelets and anti-platelet therapy. J Pharmacol Sci 2003; 93: 381–396
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 1995; 3: 64–75
   PubMedGoogle Scholar
• Michelson AD. How platelets work: platelet function and dysfunction. J Thromb 2003; 16: 7–12
   Google Scholar
• Möller HJ. Novel antipsychotics in the long-term treatment of schizophrenia. World J Biol Psychiatry 2004; 5: 9–19
   PubMed Web of Science ®Google Scholar
• Numata S, Kato O, Misawa H, Tokuda H, Kasahara T, Ohmori T. Left atrial thrombosis associated with antipsychotic drugs. Prog Neuro-Psychopharmacol Biol Psychiatry 2005; 29: 153–155
   PubMedGoogle Scholar
• Nowak P, Wachowicz B. Peroxynitrite-mediated modification of fibrinogen affects platelet aggregation and adhesion. Platelets 2002; 13: 293–299
   PubMed Web of Science ®Google Scholar
• Offermanns G. Activation of platelet function through G-protein-coupled receptors. Circ Res 2006; 99: 1293–1304
   PubMed Web of Science ®Google Scholar
• Peet M, Laugharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peorxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychophamacol 1993; 8: 151–153
   PubMed Web of Science ®Google Scholar
• Plein H, Berk M. The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol Clin Exp 2001; 16: 229–236
   PubMed Web of Science ®Google Scholar
• Ruschena D, Mullen PE, Burgess P, Codner SM, Barry-Walsh J, Drummer OH, et al. Sudden death in psychiatric patients. Br J Psychiatry 1998; 172: 331–336
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheenhan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(Supp 20)22–33
   PubMedGoogle Scholar
• Taylor D, Paton C, Kerwin R. The South London and Maudsley NHS Trust. Prescribing guidelines7th ed. Martin Dunitz, Taylor & Francis Group, London, New York 2003
   Google Scholar
• Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry 2001; 179: 63–66
   PubMed Web of Science ®Google Scholar
• The United States Pharmacopoeia Drug Information. 2000. Drug Information for the Health Care Professional. Vol I20th ed. Greenwood Village, CO, Thomson Micromedex
   Google Scholar
• von Kanel R. Platelet hyperactivity in clinical depression and the beneficial effect of antidepressant drug treatment: how strong is the evidence?. Acta Psychiatr Scand 2004; 110: 163–177
   PubMed Web of Science ®Google Scholar
• Wallaschofski H, Donne M, Eigenthaler M, Hentschel R, Faber R, Stepan H, et al. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 2001; 86: 5912–5919
   PubMed Web of Science ®Google Scholar
• Wallaschofski H, Eigenthaler M, Kiefer M, Donne M, Betina H, Gertz H, et al. Hyperprolactinemia in patients on antipsychotic drags causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol 2003; 23: 479–483
   PubMed Web of Science ®Google Scholar
• Walsh MT, Ryan M, Hillmann A, Condren R, Kenny D, Dinan T, et al. Elevated expression of integrin αIIbβIIIa in drug-naive, first episode schizophrenic patients. Biol Psychiatry 2002; 52: 874–879
   PubMed Web of Science ®Google Scholar
• Wu K. Platelet activation mechanisms and marker in arterial thrombosis. J Intern Med 1996; 239: 17–34
   PubMed Web of Science ®Google Scholar
• Yang TY, Chung KJ, Huang TL, Te-Kung CH. Massive pulmonary embolism in a young patient on clozapine therapy. J Emergency Med 2004; 27: 27–29
   PubMed Web of Science ®Google Scholar
• Yao JK, Yasaei P, van Kammen DP. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandins Leukotrienes Essent Fatty Acids 1992; 46: 39–46
   PubMedGoogle Scholar
• Yao JK, van Kammen DP, Gurklis JA, Peters JL. Platelet aggregation and dense granule secretion in schizophrenia. Psychiatry Res 1994; 54: 13–24
   PubMed Web of Science ®Google Scholar
• Yao JK, van Kammen DP, Moss HB, Sokulski DE. Decreased serotonic responsivity in platelet of drug-free patients with schizophrenia. Psychiatr Res 1996; 63: 123–132
   PubMed Web of Science ®Google Scholar
• Yao JK, Magan S, Sonel AF, Gurklis JA, Sanders R, Reddy RD. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukotriens Essent Fatty Acids 2004; 71: 171–176
   PubMed Web of Science ®Google Scholar
• Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219–1223
   PubMed Web of Science ®Google Scholar